TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Similar documents
Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

Transcatheter Aortic Valve Implantation Management of risks and complications

TAVI complication. Possible aetiology and how to manage

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Aortic valve implantation using the femoral and apical access: a single center experience.

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

Heart Team For TAVI Who and How?

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TRANSAPICAL AORTIC VALVE REPAIR

TAVR SPRING 2017 The evolution of TAVR

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

New York Valves Patient focused evidence-based approach. New York City: 6 December Antonio Colombo

Preprocedural evaluation for TAVR

Management of Difficult Aortic Root, Old and New solutions

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

TAVI in Korea, How to Avoid Conduction

The Role of Imaging in Transcatheter Aortic Valve Implantation

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Adult Cardiac Surgery

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter Valve Therapies Update

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

Transcatheter aortic valve implantation and pre-procedural risk assesment

Transcatheter Aortic Valve Implantation Present Status and Perspectives

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

Dr. Jean-Claude Laborde

VALVULOPATIE: NUOVE SOLUZIONI.

APOLLO TMVR Trial Update: Case Presentation

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital

Pre-procedural CT angiography for Transcatheter Aortic Valve Implantation: What a Radiologist Needs to Know?

The Ross Procedure: Outcomes at 20 Years

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

TAVI at Liverpool Heart & Chest Hospital. National Audit of Cardiac Services in Wales Wrexham 28/11/2012

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy

Optimal Imaging Technique Prior to TAVI -Echocardiography-

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Valvular Intervention

TAVR: It s a Career, Not Just a Procedure! Jeffrey A Southard, MD Cardiology May 5, 2012

e Corrado Tamburino, MD, PhD

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR

Transcatheter Aortic Valve Replacement TAVR

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

NON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND

> 1200 Patients

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

Potential conflicts of interest

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

Masterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach

Reverse left atrium and left ventricle remodeling after aortic valve interventions

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Percutaneous Transapical Access for Thoracic Endovascular Repair

TAVI Post operative Care. Why? Indications: Suzanne Beichner BSN, RN, PCCN Angela Robinson MSN, RN, CCRN, CVRN

VALVULAR HEART DISEASE AORTIC VALVE STENOSIS TAVR PROCEDURE

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Update 2012 Herzchirurgie

Successful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder

Transcatheter aortic valve implantation for aortic stenosis

Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC

National Intervention Council

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

Valvular Heart Disease. Dr. HANAN ALBACKR

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

PCI Update Qesaria 2009

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium

Echo Assessment Pre-TAVI

Managing the Low Output Low Gradient Aortic Stenosis Patient

Embolic Protection Devices for Transcatheter Aortic Valve Replacement

Transcription:

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Available systems: Edwards (TA and TF) and Core valve.

INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,. TAVI is an alternative.

2009 2011 2011 44 pt 1. Aortic valve area: < 1 cm 2 (<0.6 cm 2 /m 2 ) 2. Aortic valve annulus diameter: 20 mm and 27 mm, 18 mm 24mm 3. Ascending aorta: 43 mm AND 4a. Age 70 yrs OR 4c. Age 65 yrs and 1-2 comorbidities 4b. Logistic ES 15% OR

CONTRINDICATIONS General For transfemoral approach For the transapical approach 1. Aortic regurgitation 2. Aortic annulus <18 or >25 mm for balloon expandable and <20 or >27 mm for selfexpandable devices 4. Bicuspid aortic valve 5. Present of asymmetric heavy valvular calcification 6. Aortic root dimensions >4.5 cms 7. Presence of apical left lf ventricular thrombus 8. Evidence of acute myocardial infarction <30 days 9. Hypertrophic cardiomyopathy 10. Life expectancy <1 year due to non cardiac causes 1. Iliac arteries with severe calcification tortuousity and small diameter (6 9 mm), previous aorto femoral bypass 2. Severe angulation of aorta and atheroma of the outcome andcoaptation coaptation, aneurysmof the abdominal aorta with mural thrombus 3. Presence of bulky atherosclerosis of the ascending aorta and arch 1. Previous surgery of the left ventricle using a patch such as the Dor procedure 2. Calcified pericardium 3. Severe respiratory insufficiency

Age mean 79 y Sex M 52.5% F 47.7% 7% HTN 70% Lipid 77.5% DM 62.5% COPD/CLD 17.5% Prior MI 32.5% CABG 15% CHF 22.5% CR impairment 15% CVA 20% Carotid 25% AF 10% Smoking 5% LM AV distance mean 12.7 mm PVD normal mild 32.5% mod 37.5% mod sever 47.5% sever 10%

120% presentation 100% 80% 60% 40% presentation 20% 0% angina dyspnea II IV CHF syncope

Echo Dilated LV 17.5% LVH mild mod sever AV Ca mild mod sever 77.5% 10% 20% 37.5% mod sever in 80% 42.5% AR mild 52.5% mod 30% mild mod AR 82.5% sever 5% MR mild mod sever 45% 32.5 mod sever MR 42.5% 10% TR mild 22.5% mod 20% mod sever TR 27.5% sever 7.5% EF mean 50% PG MG PAP mean 86.3mmhg 50 mmhg 40mmhg

Cardiac Cath 35% 30% 25% 20% 15% 10% 5% 0% CAD N SVD 2VD 3VD LM PCI CAD

53.00% 52.00% 51.00% 50.00% 49.00% 48.00% 47.00% 46.00% 45.00% Transapical Type transfemoral Type

100% anesthesia 80% 60% 40% anesthesia 20% 0% GA CS

Echo Result 100 90 80 70 60 50 40 30 20 10 0 PG P< 0.0001 MG pre post

Mild AR/PV leak 18 16 16 14 12 10 % 8 6 7 AR/PV leak 4 2 0 0 Mild Moderate sever

Immediate Outcome NO % Edward 36 90% Core 4 10% PV leak. 4 10% success 39 97.5% Death 1 2.5% bleeding 7 16.4% RV perforation 2 5% MI 1 25% 2.5% vascular 4 10% leak 3 7.5% LM compression 2 2.5% Conversion to AVR 2 2.5%

Outcome at 0 6 Months NO % In hospital M 2 5% Post D.C M 2 5% CVA 2 5% PPM 3 7.5% ARF 3 7.5% P.EMB 2 5% PE 6 15.8% Wound infection 2 5% B.transfusion 17 43.6%

6 M 1 Y FU pre post NO 40 25 AR trivial mild 52.5% 23% mod 30% 0% sever 5% 0% MR mild mod sever TR mild mod sever 45% 32.5 10% 22.5% 20% 7.5% 47% 11% 6% 23% 6% 17% EF mean 50% 55% PAP mean 40 mmhg 35 mmhg FC II III I

FU MR 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% pre 6 M no MR mild MR mod MR sever MR

Improvement in MR severity 1.8 1.6 MR Grade 1.4 12 1.2 1 0.8 0.6 P < 0.001 Pre TAVI Post TAVI 0.4 0.2 0

FU TR 60.00% 50.00% 40.00% 30.00% pre 20.00% 6 M 10.00% 0.00% no TR mild TR mod TR sever TR

Complications One patient after transfemoral implantation of Edward Sabien valve, and the patient needed emergency CABG and died after 1 week One patient post transapical TAVI due to coronary embolization (patient died on table )

Case 1 79 y male Euro score 20% AVA 0.5, PG 95, MG 57, EF 60%, AV AM AM distance 11mm Sever AV calcification

12% mortality 10% 8% 6% 4% mortality 2% 0% 30 D 1 y

Freedom from death

No case is easy or straight forward CONCLUSION TAVI can be done with reasonably low M & M, however, we are dealing with very high risk patients, approach should be through multidisciplinary approach. Patient selection remains a learning curve. The trans apical approach is very simple BUT requires a minithoracotomy. The transfemoral approach is technically moredifficult but has advantages if the peripheral complication rate can be minimised and sheath size is reduced This is a major technology breakthrough, it's the future remain to decided. ( like PCI & stents)